Kenji Ishitsuka Selected Research

mogamulizumab

1/2022	Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
1/2022	Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab.
10/2020	Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.
1/2020	[Adult T-cell leukemia-lymphoma with severe hepatic damage and fluid retention successfully treated with mogamulizumab].
5/2019	Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
1/2019	Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.
1/2018	Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
10/2017	Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
10/2015	Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.
6/2015	Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenji Ishitsuka Research Topics

Disease

32	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2022 - 05/2002
25	Multiple Myeloma 01/2022 - 04/2004
24	Neoplasms (Cancer) 01/2022 - 03/2002
13	Lymphoma (Lymphomas) 01/2022 - 09/2008
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 10/2015
4	Infections 01/2020 - 02/2009
3	Necrosis 02/2007 - 04/2004
3	Acute Promyelocytic Leukemia 04/2004 - 05/2002
2	Lymphopenia (Lymphocytopenia) 11/2019 - 11/2009
2	Neutropenia 01/2019 - 11/2009
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2009 - 11/2009
2	Febrile Neutropenia 11/2009 - 02/2009
2	Hypoxia (Hypoxemia) 11/2004 - 03/2002
2	Leukemia 11/2004 - 03/2002
1	Wounds and Injuries (Trauma) 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2020
1	Hyperbilirubinemia 01/2020
1	Lymphomatoid Papulosis 11/2019
1	Drug-Related Side Effects and Adverse Reactions 05/2019
1	Thrombocytopenia (Thrombopenia) 01/2019
1	Renal Cell Carcinoma (Grawitz Tumor) 06/2018
1	Pulmonary Hypertension 01/2018
1	POEMS Syndrome (Syndrome, POEMS) 01/2018
1	Lymphadenopathy 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017
1	T-Cell Lymphoma (Lymphoma, T Cell) 06/2016
1	Colitis 10/2015

Drug/Important Bio-Agent (IBA)

12	Bortezomib (Velcade)FDA Link 09/2015 - 10/2004
11	mogamulizumabIBA 01/2022 - 03/2012
8	Interleukin-6 (Interleukin 6)IBA 02/2007 - 11/2004
7	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020 - 07/2005
6	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018 - 07/2005
5	CaspasesIBA 12/2019 - 03/2002
5	Arsenic Trioxide (Trisenox)FDA Link 03/2008 - 05/2002
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2007 - 10/2004
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2020 - 11/2009
4	CCR4 ReceptorsIBA 05/2019 - 03/2012
4	Monoclonal AntibodiesIBA 05/2019 - 03/2012
3	Etoposide (VP 16)FDA LinkGeneric 12/2021 - 01/2019
3	Vincristine (Oncovin)FDA LinkGeneric 12/2020 - 11/2009
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2007
3	Proteins (Proteins, Gene)FDA Link 08/2017 - 04/2012
3	Interferon-alpha (Interferon Alfa)IBA 08/2011 - 05/2007
3	Zidovudine (Retrovir)FDA LinkGeneric 12/2010 - 03/2008
3	InterferonsIBA 12/2010 - 05/2007
3	p38 Mitogen-Activated Protein KinasesIBA 05/2008 - 11/2004
3	CytokinesIBA 10/2006 - 11/2004
3	Biological ProductsIBA 10/2006 - 11/2004
3	Pharmaceutical PreparationsIBA 03/2006 - 07/2005
2	Carboplatin (JM8)FDA LinkGeneric 12/2020 - 01/2019
2	Vindesine (Vindesin)IBA 12/2020 - 01/2019
2	Adenosine Monophosphate (AMP)IBA 12/2020 - 01/2019
2	Prednisone (Sone)FDA LinkGeneric 12/2020 - 01/2019
2	ranimustineIBA 12/2020 - 01/2019
2	Immunoconjugates (Immunoconjugate)IBA 08/2020 - 04/2008
2	Lenalidomide (CC 5013)FDA Link 01/2018 - 12/2004
2	AlkaloidsIBA 01/2017 - 07/2015
2	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2017 - 07/2011
2	WithanolidesIBA 04/2013 - 07/2011
2	Glutathione (Reduced Glutathione)IBA 07/2007 - 09/2002
2	Melphalan (Alkeran)FDA LinkGeneric 12/2006 - 10/2006
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2006 - 05/2002
2	Insulin-Like Growth Factor I (IGF-1)IBA 10/2006 - 08/2005
2	Etodolac (Lodine)FDA LinkGeneric 07/2006 - 07/2005
1	Chemokine ReceptorsIBA 01/2022
1	SRT1720IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Sirtuin 1IBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Indicators and Reagents (Reagents)IBA 12/2021
1	LignansIBA 12/2021
1	DiterpenesIBA 12/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020
1	Nucleic AcidsIBA 01/2020
1	CardenolidesIBA 01/2020
1	dorsomorphinIBA 01/2020
1	AMP-Activated Protein KinasesIBA 01/2020
1	adenovirus receptorIBA 05/2019
1	SurvivinIBA 05/2019
1	STF 62247IBA 06/2018
1	CC ChemokinesIBA 10/2017
1	Transcription Factors (Transcription Factor)IBA 08/2017
1	UbiquitinIBA 08/2017
1	F-Box-WD Repeat-Containing Protein 7IBA 08/2017
1	Ligases (Synthetase)IBA 08/2017
1	Messenger RNA (mRNA)IBA 08/2017
1	CoumarinsIBA 01/2017
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 06/2016
1	IntegrinsIBA 04/2016

Therapy/Procedure

13	Therapeutics 01/2022 - 03/2002
10	Drug Therapy (Chemotherapy) 01/2020 - 03/2008
5	Hematopoietic Stem Cell Transplantation 01/2022 - 12/2015
3	Stem Cell Transplantation 01/2019 - 03/2008
1	Chemoradiotherapy 11/2019
1	Transplantation 01/2019
1	Combination Drug Therapy (Combination Chemotherapy) 12/2015